Targets › GABRA
1 program from 1 company in 5 trials: 2 Phase 3, 2 Phase 2, 1 Phase 1; Neurology, Psychiatry; next expected readout Jun 2027.
Open in Phaseline: the race on GABRA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Rapport Therapeutics | RAP-219 GABA-A positive allosteric modulator | GABRA | Phase 3 | Focal Seizure; Bipolar 1 Disorder; Focal Epilepsy; Epilepsy | Jun 2027 |
Focal Seizure (2) Bipolar 1 Disorder (1) Focal Epilepsy (1) Epilepsy (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.